Molecular Detection of Prostate Cancer by Methylation Analysis of Plasminogen Activator Inhibitor-1 in Serum DNA
- *Corresponding Author:
- Mario Menschikowski
Fetscherstrasse 74, D01307 Dresden, Germany
E-mail: [email protected]
Received Date: May 22, 2015 Accepted Date: June 16, 2015 Published Date: June 18, 2015
Citation: Nacke B, Hagelgans A, Fuessel S, Wirth MP, Siegert G, et al. (2015) Molecular Detection of Prostate Cancer by Methylation Analysis of Plasminogen Activator Inhibitor-1 in Serum DNA. J Cell Sci Ther 6:210. doi:10.4172/2157-7013.1000210
Copyright: © 2015 Nacke B, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: Epigenetic modifications are common in malignant tissues. Here we analyzed the methylation degree of plasminogen activator inhibitor 1 (PAI-1) gene in comparison to the methylation of glutathione-stransferase- π (GSTP1) gene in prostate cancer (PCa).
Methods: PAI-1 hypermethylation was studied using methylation-sensitive high resolution melting (MS-HRM) analysis of bisulfite-modified DNA and methylation-sensitive restriction endonuclease based quantitative PCR (MSRE-qPCR) on unmodified genomic DNA.
Results: Data, obtained by these two methods, correlate closely. Methylation levels of PAI-1 analyzed in tissue specimens and serum samples were nearly similar. The diagnostic performance of the MSRE-qPCR assay characterized by AUC values was 0.944 and 0.937 for PAI-1 and GSTP1, respectively. Combination of both markers resulted in higher values of AUC, sensitivity and specificity.
Conclusion: MSRE-qPCR based methylation analysis of PAI-1 gene and especially - in combination with GSTP1 gene may have potential as epigenetic marker of PCa in biological fluids.